Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 01, 2022

BUY
$8.63 - $15.52 $568,751 - $1.02 Million
65,904 New
65,904 $585,000
Q2 2022

Aug 09, 2022

SELL
$8.59 - $20.77 $6,013 - $14,539
-700 Reduced 1.05%
65,904 $833,000
Q1 2022

May 12, 2022

BUY
$15.52 - $35.65 $153,648 - $352,935
9,900 Added 17.46%
66,604 $1.3 Million
Q3 2021

Nov 15, 2021

BUY
$35.66 - $42.94 $210,393 - $253,346
5,900 Added 11.61%
56,704 $2.09 Million
Q2 2021

Aug 11, 2021

SELL
$23.7 - $39.27 $94,800 - $157,080
-4,000 Reduced 7.3%
50,804 $1.99 Million
Q1 2021

May 17, 2021

BUY
$27.01 - $36.8 $270,100 - $368,000
10,000 Added 22.32%
54,804 $1.54 Million
Q4 2020

Feb 16, 2021

SELL
$27.51 - $34.36 $22,008 - $27,488
-800 Reduced 1.75%
44,804 $1.43 Million
Q3 2020

Nov 17, 2020

SELL
$25.8 - $34.61 $10.3 Million - $13.8 Million
-399,369 Reduced 89.75%
45,604 $1.47 Million
Q3 2020

Nov 13, 2020

BUY
$25.8 - $34.61 $10.3 Million - $13.8 Million
399,369 Added 875.73%
444,973 $14.4 Million
Q2 2020

Aug 17, 2020

BUY
$17.65 - $28.05 $37,065 - $58,905
2,100 Added 4.83%
45,604 $1.25 Million
Q1 2020

May 14, 2020

SELL
$15.19 - $29.51 $18,228 - $35,412
-1,200 Reduced 2.68%
43,504 $778,000
Q4 2019

Feb 11, 2020

SELL
$17.17 - $25.95 $187,153 - $282,855
-10,900 Reduced 19.6%
44,704 $1.12 Million
Q2 2019

Jul 31, 2019

BUY
$22.0 - $31.78 $640,200 - $924,798
29,100 Added 109.79%
55,604 $0
Q4 2018

Feb 12, 2019

BUY
$23.09 - $37.69 $611,977 - $998,935
26,504 New
26,504 $569,000

Others Institutions Holding HCM

About HUTCHMED (China) Ltd


  • Ticker HCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 172,955,008
  • Market Cap $3.11B
  • Description
  • HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...
More about HCM
Track This Portfolio

Track Great West Life Assurance CO Portfolio

Follow Great West Life Assurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great West Life Assurance CO , based on Form 13F filings with the SEC.

News

Stay updated on Great West Life Assurance CO with notifications on news.